Serum Vitronectin and Related Molecules in Chronic Kidney Disease

  • Ekhlas Abdallah Hassan1, Fayhaa M. Khaleel2
Keywords: CKD, Vitronectin, PAI-1, TGF-B.

Abstract

One in eight people are reported to have chronic kidney disease (CKD). The renal function slowly deteriorates
when nephrons become impaired by inflammatory and fibrotic processes. In this study, the relationships
between vitronectin (VTN), plasminogen activator inhibitor-1 (PAI-1) and growth factor translation β1
(TGF-β1) are studied in CKD to assess the role as predict about progression stages of diseases. 105 patients
with early stages (1 to 3) of CKD and 35-69 age matched healthy controls were included in the study.
The VTN, PAI-1, TGF-Bate levels of all participants were examined by Enzyme linked immune sorbent
assay, creatinine, and urea by enzymatic method . Early morning urine sample was collected to be used for
determination albumin creatinine ratio in patient with early stages of CKD. The renal function tests were
significantly elevated in CKD group compared with healthy controls. The serum concentration of VTN
increase in early stages(1-2) of CKD and decrease significantly with progression of disease (stage 3). Serum
PAI-1 antigen level increased significantly. With the development of CKD, the effective role of TFG-β
became more severe,the correlation among VTN, TGF-β and PAI-1 was positive.
Conclusions: These results indicate that VTN is important indicator for predict of CKD progression and
both VTN, PAI-1 are connected to TGF-β’s active form and can be used as a prediction for progression of
CKD.

Author Biography

Ekhlas Abdallah Hassan1, Fayhaa M. Khaleel2

1Lecturer, 2Assistant Professor, Chemistry Dept. College of Science for Women,
Baghdad University, Baghdad, Iraq

Published
2020-05-22
How to Cite
Ekhlas Abdallah Hassan1, Fayhaa M. Khaleel2. (2020). Serum Vitronectin and Related Molecules in Chronic Kidney Disease. Medico Legal Update, 20(2), 339-347. Retrieved from http://ijop.net/index.php/mlu/article/view/1126